<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210406050871N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-04-25</date_registration>
      <primary_sponsor>Shahroud University of Medical Sciences</primary_sponsor>
      <public_title>The effect of percutaneous electrical nerve stimulation on the respiratory outcomes of patients with Covid-19 with moderate pulmonary involvement</public_title>
      <acronym></acronym>
      <scientific_title>The effect of percutaneous electrical nerve stimulation on the respiratory outcomes of patients with Covid-19 with moderate pulmonary involvement: A clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-04-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>84</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/55531</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The 4-block block randomization method is used to create a random allocation sequence in this study because the participants gradually enter the study and also the number of assignments to each group is equal.
In this research, the random allocation sequence is obtained by the methodology consultant with the software.
After creating a random sequence, 84 opaque envelopes with wrappers are prepared and each random sequence is recorded on a card and placed inside the envelopes and closed. In order to maintain the sequence and to prevent disruption, the envelopes will be numbered and placed in a box.
Eligible participants will be registered by the principal investigator in the order of their arrival, and an envelope will be opened in the order in which the person enters the study, one of the envelopes will be opened, and thus his / her assigned group will be revealed. Individuals will be placed equally in each group, Blinding description: The present study is three-blind and in addition to the participants, the data collector (outcome assessor) and the statistical analyst are not aware of the allocation of groups.
The data collector who is involved in collecting and recording information such as respiration rate, pulse, oxygen saturation, etc., or in completing questionnaires will be unaware of the group of individuals.
The analyst will also be unaware of the group of people.
It should be noted that the physiotherapist who is responsible for the intervention and is known as the caregiver, by contacting the research colleague who has the sequence, becomes aware of the group to which each person is assigned and performs the intervention.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Covid-19.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: is performed by a researcher who does not know the assignment of groups under the supervision of an Acu-TENS trained physiotherapist for the intervention group in such a way that the patient is in a sitting or semi-sitting position and by re-controlling the skin of the area for lesions, Two plastic electrodes 5 × 5 cm and sticky are placed on both sides of the spine appendage of 7 cervical vertebrae; The electrodes are connected to NOVIN701P PLUS-STIMULATOR device made in Iran and serial number AX212088 and the frequency is set to 4 Hz and the pulse is set to 200 MICROSEC with a duration of 45 minutes. Intervention 2: Control group: by a researcher who does not know the assignment of groups under the supervision of a trained physiotherapist,  ineffective Acu-TENS was performed for the control group in such a way that the patient is placed in a sitting or semi-sitting position and by re-controlling, the skin of in view of the lesion, two plastic electrodes of 5* 5 cm and adhesive are placed in an ineffective point for breathing, the front of the chest; The electrodes are connected to NOVIN701P PLUS-STIMULATOR device made in Iran and serial number AX212088 and the frequency is set to 4 Hz and the pulse is set to 200 MICROSEC with a duration of 45 minutes.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only part of the data, such as information about the main outcome, can be shared.

When:
Access period starts 6 months after the results are published

To whom:
Only for researchers working in academic and scientific institutions

Conditions:
If necessary, contact Dr. Mahboobeh Khajeh and if there is a reasonable justification for use in scientific purposes

Where to obtain:
Dr. Mahboobeh Khajeh
Shahroud, 7thTir Square, Shahroud University of Medical Sciences;
School of Nursing and Midwifery
02332395054
m_khajeh@ymail.com

How to obtain:
By phone call or by email and registration of the request and stating the reason and purpose of the logical and approved up to two weeks

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahboobeh Khajeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>7th Tir Square. Shahroud University of Medical Sciences</address>
        <city>شاهرود</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۳۶۱۴۷-۷۳۹۴۷</zip>
        <telephone>+98 23 3239 5054</telephone>
        <email>m_khajeh@ymail.com</email>
        <affiliation>Shahroud University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahboobeh Khajeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>7th Tir Square. Shahroud University of Medical Sciences</address>
        <city>شاهرود</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۳۶۱۴۷-۷۳۹۴۷</zip>
        <telephone>+98 23 3239 5054</telephone>
        <email>m_khajeh@ymail.com</email>
        <affiliation>Shahroud University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Confirmation of Covid-19 diagnosis based on PCR test results or CT Scan findings (Ground Glass view) by physician
Age over 18 and under 70 years
Use the same treatment protocol for patients
Existence of moderate pulmonary involvement (SpO2 between 90 to 93% and pulmonary involvement less than 50%) and the patient being in the second phase of Covid-19 disease according to the guideline of the Ministry of Health</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Drug addiction
Cigarette addiction
Advanced metastatic cancer
Congestive heart failure (grades 3 and 4)
Kidney failure requires dialysis
History of mechanical ventilation before intervention
Existence of cardiac pacemaker
Cardiac conduction disorders
History of allergies and skin sensitivities in the area of ​​the electrodes
The presence of a skin lesion in the area where the electrodes are placed
Hospitalized patients with other clinical manifestations of Covid-19 and no pulmonary involvement
Continuous use of bronchodilators
Having liver failure
Moderate to severe scoliosis
Obesity (BMI above 35)
Psychological illnesses lead to lack of patient cooperation
Cerebrovascular disorders
Having COPD
Having uncontrolled diabetes
Inability and prohibition to be in a semi-sitting position for any reason</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>U07.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Coronavirus disease (COVID-19)</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: is performed by a researcher who does not know the assignment of groups under the supervision of an Acu-TENS trained physiotherapist for the intervention group in such a way that the patient is in a sitting or semi-sitting position and by re-controlling the skin of the area for lesions, Two plastic electrodes 5 × 5 cm and sticky are placed on both sides of the spine appendage of 7 cervical vertebrae; The electrodes are connected to NOVIN701P PLUS-STIMULATOR device made in Iran and serial number AX212088 and the frequency is set to 4 Hz and the pulse is set to 200 MICROSEC with a duration of 45 minutes.</i_keyword>
      <i_keyword>Control group: by a researcher who does not know the assignment of groups under the supervision of a trained physiotherapist,  ineffective Acu-TENS was performed for the control group in such a way that the patient is placed in a sitting or semi-sitting position and by re-controlling, the skin of in view of the lesion, two plastic electrodes of 5* 5 cm and adhesive are placed in an ineffective point for breathing, the front of the chest; The electrodes are connected to NOVIN701P PLUS-STIMULATOR device made in Iran and serial number AX212088 and the frequency is set to 4 Hz and the pulse is set to 200 MICROSEC with a duration of 45 minutes.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Percentage of arterial blood oxygen saturation. Timepoint: Daily for up to 4 days before and after the intervention. Method of measurement: Finger pulse oximeter device and monitor.</prim_outcome>
      <prim_outcome>Need for mechanical ventilation. Timepoint: 4, 8 and 12 days after the intervention. Method of measurement: Checklist.</prim_outcome>
      <prim_outcome>Death and survival. Timepoint: until the end of hospitalization. Method of measurement: Checklist.</prim_outcome>
      <prim_outcome>Vital signs (RR,HR). Timepoint: Daily for up to 4 days before and after the intervention. Method of measurement: Count the respiratory rate and heart rate in a minute and record them in a checklist.</prim_outcome>
      <prim_outcome>Severity of breathing (Dyspnea). Timepoint: Daily for up to 4 days before and after the intervention. Method of measurement: Visual Analogue scale for dyspnea (VASD).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahroud University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-04-11</approval_date>
        <contact_name>Ethics Committee of Shahroud University of Medical Sciences</contact_name>
        <contact_address>7th Tir Square, Shahroud University of Medical Sciences Shahroud Semnan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
